Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary

November 4, 2021

NASDAQ US Health Care Pharmaceuticals earnings 56 min

Earnings Call Speaker Segments

Jennifer Ruddock

executive
#1

Thanks, Crystal, and good afternoon to all of you. We appreciate everyone being here today. Joining us on this call are Howard Robin, who serves as our President and CEO; Gil Labrucherie, our COO and CFO; Dr. Jonathan Zalevsky, our Chief of Research and Development; and Dr. Dimitry Nuyten, our Chief Medical Officer. During this call, we anticipate making forward-looking statements about our business, covering clinical trial enrollments and clinical trial results, the timing and plans for upcoming trials, the timing and plans for upcoming clinical data presentations, how our drug candidates might perform therapeutically, outcomes and plans related to health authority regulatory actions and decisions, financial guidance, and certain other statements concerning the future of our business. Since these forward-looking statements concern the future, they carry inherent uncertainties and risks that are hard to predict, and many of them lie beyond our control. Our actual results could differ materially from what these statements suggest. Significant risks and uncertainties are described in the Form 10-Q filed on August 6, 2021, which you can find at sec.gov. We assume no obligation to update any of these forward-looking statements, whether because of new information, future developments, or otherwise. A webcast of this call will be accessible on the IR page of Nektar's website at nektar.com. Before I turn things over to Howard, I want to remind everyone that we are dialing in from different locations. I will moderate the Q&A session for our team so that we can steer clear of technical issues during the session, and we thank you for your patience. Having said that, I would like to hand the call over to our President and CEO, Howard Robin. Howard?

Howard Robin

executive
#2

Appreciate that, Jennifer. And thank you everyone for being on the call today; during this quarter, we kept moving forward with both our I-O and immuno-oncology pipelines. What we've accomplished has laid the groundwork for what should be a transformative stretch for Nektar, beginning with a set of expected pivotal and key mid-stage data readouts spanning our portfolio over the course of 2022, and the readout people are watching most closely — from our Phase III trial of BEMPEG in melanoma — should arrive in the early portion of 2022; so I'll start today with BEMPEG, the program furthest along in our clinic. That IL-2 pathway agonist of ours is in development alongside checkpoint inhibitors, NIVO and PEMBRO, across several sizable frontline and adjuvant tumor settings. Alongside our partner, BMS, we are pushing forward 5 active registrational trials of BEMPEG and NIVO as part of the joint development plan we share. 3 of those trials remain on schedule to deliver top line data during the first half of 2022. Back in October, BMS let us know that enrollment had been completed in the Phase III trial of BEMPEG plus nivo in previously untreated metastatic melanoma. The timing currently forecast for the ORR and PFS analysis from that trial is at some point in the early part of 2022. On top of that, we expect data from the Phase III trial in renal cell carcinoma along with the Phase II accelerated approval trial in cisplatin-ineligible bladder cancer during the first half of 2022, coming after the melanoma top line data. Should data from these 3 trials come back positive, that would back a series of BLA filings for BEMPEG, and then commercial launches for the combination treatment of BEMPEG plus nivo starting as early as late 2022 or early 2023. The registrational program we run with BMS also covers 2 further large Phase III trials, one in adjuvant melanoma and another in muscle invasive bladder cancer. Those indications present a chance to substantially grow the patient populations BEMPEG can serve and to potentially help patients by treating them earlier in the course of their disease. We're especially enthusiastic about the adjuvant melanoma trial, which is running ahead of its enrollment projections, having reached almost half of the target enrollment of 950 patients as of the beginning of November. These trials carry longer timelines with them, since they sit in earlier settings with larger target enrollment sizes. Data from these trials are expected beginning in 2024. Beyond that, BMS is running a Phase II trial in renal cell carcinoma for BEMPEG plus nivo with a TKI to clear the path for future development of a TKI inclusive regimen, building on their recent successful approval of nivo plus cabo. We also have a sixth registrational program, which is a combination trial of BEMPEG plus pembro in head and neck cancer. The Phase II/III trial in head and neck cancer is currently enrolling patients. We're excited about what this doublet could do to increase and deepen responses versus pembro alone in this immune sensitive cancer. Pembro holds roughly 70% share of the first-line market when it comes to treating head and neck cancer patients who are PD-L1 positive, and in our view there's a distinct chance to boost outcomes by pairing our ILT mechanism with a top-tier checkpoint inhibitor in that setting. As we've said before, our early approach with BEMPEG combined with pembro focuses on the biggest settings where pembro serves as the gold standard of care in head and neck cancer, exactly as I just laid out. Then, when it comes to non-small cell lung cancer, we're conducting a Phase II trial known as PROPEL. Regarding PROPEL, our plan is to share the initial Phase II data at the ESMO I-O meeting in December, and Dimitry will give an update on that study during this call. Those initial data will cover roughly 60 to 70 patients who received the BEMPEG plus PEMBRO doublet, with differing PD-L1 expression levels. At ESMO I-O, we'll hold an analyst call featuring Dr. Daniel Johnson from the Ashner Medical Center in Louisiana, and I'll let Dimitry say more about this upcoming presentation shortly. We've now moved the PROPEL study forward by adding chemotherapy arms to the BEMPEG plus PEMBRO regimen in both squamous and non-squamous patients whose PD-L1 expression levels are under 50%. Adding chemotherapy lets us contemplate a registrational strategy for BEMPEG in non-small cell lung cancer among these populations, which right now have the greatest unmet need for better therapeutic choices. As you're aware, non-small cell lung cancer isn't as immune-sensitive as tumorous melanoma; therefore the chemotherapy combination with PEMBRO has become a standard of care for these patients, in order to get past this more immune resistant setting; specifically, the under 1% patient population is one we're heavily focused on as a future potential registrational strategy for BEMPEG, because of its mechanism of upregulating PD-L1 together with a checkpoint and its capacity to potentially deepen response and extend response duration, which we know could translate into longer survival. On top of that, while PEMBRO in chemotherapy has bettered overall survival in PD-L1 negative non-small cell lung cancer patients, its benefit remains limited to under 2 years. We've also achieved notable progress with our second immuno-oncology candidate, NKTR-255, an IL-15 agonist that has shown it can expand natural killer cells, CD8 positive T cells and memory T cells. Because of these unique attributes, NKTR-255 could tackle treatment needs in both liquid and solid tumors. Our development plan starts by focusing on combining NKTR-255 with antibodies that rely on antibody-dependent cellular toxicity, or ADCC, to kill cancer cells, since these antibodies need functional NK cells for their mechanism of action. Next week at SITC, we'll share our first early data from patients in the initial dose escalation cohorts of the ongoing Phase I solid tumor study, which is evaluating NKTR-255 plus cetuximab in patients with either colorectal or head and neck cancer. We're continuing to increase doses in this trial, and it's great that the data got picked for a late-breaking abstract. Next Friday, November 12, at 12 noon Eastern Time, we'll hold a conference call featuring Dr. Alan Tan of Rush Medical Center to go through these findings more thoroughly. We also shared today that results from the ongoing dose escalation portion of the Phase I hematological malignancies study were accepted for a presentation at ASH in December. According to the pharmacodynamic information in the abstract out today, there's a sustained rise in NK and CD8+ T cells, along with a proliferative capacity in those cells. We're eager to share further specifics at ASH. Back in September, we disclosed our initial partnership for NKTR-255 with Merck KGaA and Pfizer. This alliance moves the NKTR-255 program into its first comparative study, focused on an on-label indication for Merck KGaA's avelumab as maintenance treatment in bladder cancer. In contrast to other approved anti-PD-L1 agents, avelumab has demonstrated in preclinical work that it triggers tumor cell lysis through the ADCC mechanism. Consequently, Merck and we are enthusiastic about investigating possible synergies from pairing it with an NK cell stimulator like NKTR-255. As part of the Phase II JAVELIN bladder medley umbrella trial, Merck will assess NKTR-255 alongside avelumab.

Howard Robin

executive
#3

We are thrilled that NKTR-255 has been selected for this umbrella study, and it's the sole IL-15 agent being included. Merck is going to handle running that study, which should kick off in Q1 of 2022, while Nektar will provide NKTR-255. JZ is going to go through the trial in greater depth shortly. The third cytokine in our lineup is NKTR-358, which we're working on alongside Eli Lilly to tackle a wide variety of autoimmune and inflammatory conditions. NKTR-358 goes after the IL-2 receptor complex in order to stimulate the proliferation of potent inhibitory immune cells called regulatory T cells, and in doing so, restores balance to the immune system. This program makes us proud, and no other company besides us has reported a multiple dose effect of their agents on target T regulatory cells in patients. Alongside our partner Lilly, we hold the lead in this area thanks to the advanced clinical stage of the NKTR-358 program and the broad scope of development being run in parallel across several major autoimmune indications. As was planned from the beginning of our collaboration with Lilly, the development program, manufacturing included, has now been handed over to them. Lilly right now has NKTR-358 clinical trials running, 4 clinical trials running: a Phase II study in lupus; a Phase II study in ulcerative colitis; and 2 ongoing separate Phase Ib studies in psoriasis and atopic dermatitis. We anticipate data readouts from these Lilly-run studies over the coming 6 to 12 months, and Lilly also intends to add 2 more Phase II studies to the program before long. Past our extensive clinical portfolio, we keep investing in immune science and cytokine biology to fuel the next wave of IND candidates. Operationally speaking, our balance sheet is exceptionally strong and we expect to close out the year with more than $800 million in cash. That cash position, along with backing from our strategic collaborations and the potential for as much as $1.4 billion in regulatory approval and sales milestones for BEMPEG in the U.S., Europe and Japan, gives us the financial footing to carry out our robust development strategy; all of us are eagerly awaiting with anticipation the registrational study readouts for BEMPEG in melanoma, RCC in bladder cancer in the first part of next year. I'll now hand the call over to our Chief Medical Officer, Dr. Dimitry Nuyten. Dimitry?

Dimitry Nuyten

executive
#4

Thanks, Howard. I want to give you a brief status report on the BEMPEG program and when we expect the registrational trials to read out — everything is proceeding as we previously told you it would. Starting with the Phase III trial in first-line metastatic melanoma, which involves 760 patients and is being conducted by our collaborator, BMS. Both we and BMS are eagerly anticipating the completion of that trial and the data it will produce. As Howard mentioned, BMS let us know back in October that enrollment had been completed in full. BMS brings a strong history in melanoma, having successfully run numerous registrational trials for IO agents. Melanoma has shown itself to be a tumor setting that responds strongly to immune-based approaches, and the potential of BEMPEG — an agent capable of deepening and extending responses for these patients — is something we find very encouraging. In August 2019, the FDA granted breakthrough therapy designation to the combination of BEMPEG plus nivolumab, on the basis of this norm observed in melanoma patients. Should the Phase III results look comparable, we see a distinctive opportunity for the BEMPEG–nivolumab doublet to become a new standard of care in this indication. As we mentioned three months ago, BMS has communicated its plan to perform an initial analysis of data covering both the ORR and PFS endpoints once a certain number of events, as specified in the statistical analysis plan for the PFS endpoint, have occurred. According to BMS's current projections, that analysis of data may take place in the early portion of 2022. Because of the breakthrough therapy designation I referenced above for this indication, we think we could move quickly toward a regulatory filing should the data support it. Naturally, since the PFS analysis is driven by events, several considerations — among them the actual rate at which PFS events accumulate — could affect when the analysis happens. Turning to the next trial, which Nektar is conducting: it's a Phase III study in first-line renal cell carcinoma with 620 patients, testing BEMPEG plus nivolumab against a TKI chosen by the physician, either sunitinib or cabozantinib; we anticipate possibly reaching the first interim analysis for the primary overall survival endpoint at some point during the second quarter of 2022. In this tumor type specifically, BMS and Nektar are pursuing a broad development strategy for BEMPEG plus nivolumab. In addition, BMS is running a randomized Phase II trial in RCC with 250 patients that combines BEMPEG plus nivolumab with cabozantinib from Exelixis, enabling a comparison against the nivolumab–cabozantinib treatment and laying the groundwork for a TKI-inclusive regimen in RCC featuring BEMPEG and nivolumab. Earlier in the year, BMS and Nektar broadened the RCC strategy by adding a new partnership with Exelixis, which will run a trial assessing BEMPEG plus nivolumab alongside their innovative next-generation TKI, XL92. That trial will also cover other GEO cancers, urothelial cancer among them. Regarding the Phase II trial in first-line eligible urothelial carcinoma, which Nektar is running, the design is intended to provide the foundation for a possible accelerated approval filing. This research involves roughly 110 individuals with urothelial carcinoma who cannot receive cisplatinum and whose baseline CPS score measures 10 or less, which indicates their level of PD-L1 expression. When it comes to this trial's primary endpoint, that would be overall response along with duration of response — excuse me — as assessed through central radiology review. Within this study, our aim is a median follow-up of 18 months so we can measure duration of response, and we anticipate the earliest data from this trial arriving during the first half of 2022 too. Howard mentioned previously that the BEMPEG nivolumab program likewise features sizable Phase III trials in muscle invasive bladder cancer as well as adjuvant melanoma. The Phase III periadjuvant muscle invasive bladder cancer study, conducted by BMS, is currently enrolling roughly 540 patients, each receiving either BEMPEG plus nivolumab or nivolumab alone — initially in a neoadjuvant setting ahead of radical cystectomy, followed by the adjuvant setting across a 12-month treatment window after their operation. Since treatment in this study spans a longer duration, we anticipate the earliest data readout landing in 2024 or 2025; furthermore, this trial is intended to act as a confirmatory study supporting our planned potential accelerated approval within the metastatic cis-ineligible urothelial carcinoma setting. Turning to the second one, the Phase III adjuvant melanoma trial, which Nektar is conducting. This research is enrolling approximately 950 patients in total, with a 12-month treatment period following surgery and an endpoint of recurrence-free survival assessed by blinded independent central review; enrollment in this study keeps moving quickly and, per Howard's earlier remarks, is currently running ahead of schedule. Come November 1, we had 450 patients enrolled, something we see as reflecting the enthusiasm among physicians and patients regarding what BEMPEG plus nivolumab could offer in melanoma. This adjuvant study is built to establish BEMPEG as the standard of care for treating melanoma, extending upon the recent approval of nivolumab for this indication. We expect initial data from this study during 2024. Now I'll shift to the PROPEL study, which assesses BEMPEG plus pembrolizumab in non-small cell lung cancer. As Howard mentioned, we intend to share the initial data from PROPEL in non-small cell lung cancer among patients given the BEMPEG plus pembrolizumab doublet at ESMO I-O this December. What was submitted and accepted as an abstract for ESMO I-O served purely as a placeholder and contained nothing beyond the initial safety evaluation. That happened because, when the abstract submission deadline arrived, the blind independent review of the PROPEL data set had not yet been finished. Howard also noted that we'll hold an analyst event surrounding ESMO I-O, featuring the invited investigator, Dr. Daniel Johnson of the Ochsner Cancer Center, who enrolled numerous patients both within the dose escalation portion of the trial and within the non-small cell lung cancer expansion portion of the study, and who has witnessed a positive experience with the doublet. Just to recap, what we're presenting will contain information on roughly 60 to 70 patients who have squamous or nonsquamous non-small cell lung cancer. Those patients fall into 3 distinct PD-L1 expression subgroups. This was set up as a single-arm trial intended to assess how the doublet performs relative to historical overall response rates seen with single-agent pembrolizumab, and those rates are thoroughly documented from 2 registrational trials. When it comes to non-small cell lung cancer, a disease that generally isn't viewed as immune-sensitive, we understand that where a patient's tumor PD-L1 expression stands at baseline can determine what clinical benefit should be anticipated from pembrolizumab. To give you a reference point, we describe pembrolizumab monotherapy as producing an overall response rate of roughly 8% among patients whose PD-L1 tumor expression is less than 1, approximately 15% among those with PD-L1 tumor expression of 1 to 49, and for patients whose PD-L1 tumor expression is greater or equal to 50%, single-agent pembrolizumab yields an overall response rate of about 40% to 45%. Even though this trial was open-label, as we've said before, we concluded that we ought to remain blinded to the efficacy data until the blinded independent review had been completed.

Dimitry Nuyten

executive
#5

The database for the study's initial analysis has just been locked, and we now have the pooled efficacy results—this includes a thorough assessment of efficacy among study patients—from the blinded independent review covering the doublet arms in non-small cell lung cancer within PROPEL. Ahead of the ESMO I-O Congress, I'd like to review a handful of early observations drawn from that report. First off, we're encouraged by multiple findings that reinforce our confidence in the additional benefit BEMPEG offers beyond pembrolizumab by itself. In a number of cohorts, the responses we observed were both deep and long-lasting. That includes how many patients achieved complete responses, and how many experienced a 100% reduction in tumor volume. With pembrolizumab alone, or even when combining chemotherapy with pembrolizumab, that kind of result is uncommon. Because we had already enrolled patients before an independent PD-L1 baseline assessment had been completed, we ended up overenrolling both the under 1% cohort and the 1% to 49% cohort. As a result, we had about 28 efficacy evaluable patients in each cohort, compared with our original goals of 20 and 18 patients. When we looked at the group with PD-L1 above 50%, there were 15 patients total who could be evaluated for efficacy. In the group with PD-L1 under 1%, meaning negative status, the response rate we observed was twice what's seen with pembrolizumab by itself. Of note, 2 patients in this cohort experienced a 100% decrease in their RECIST target lesions. In one case, this occurred at the very first scan taken during treatment. For the other patient, the reduction came about progressively. Median duration of response hasn't been reached yet in this cohort, and the median depth of response right now stands at a notable 77% shrinkage in tumor volume among the responders here. We were quite encouraged to observe that the response rate doubled, and that responses went deep, among patients whose tumors are PD-L1 negative — a group that historically has had only limited benefit from checkpoint therapy given as a single agent. In the cohort with PD-L1 expression from 1% to 49%, although extended stable disease was achieved by more than half of those patients, the overall response rate came in at a low single-digit figure, and that finding caught us off guard. Even though these results were unexpected, we should point out that we identified 3 notable differences between the patient population that was enrolled in the 1 to 49 cohort and the populations studied with pembrolizumab as a single agent. Let me start with the biggest finding: among the patients in that 1% to 49% group, one in four — 25% — had received chemotherapy earlier, either for stage 3 disease or as adjuvant therapy for stage 1 or 2 disease, prior to enrolling in the trial. The protocol permitted this, provided at least 6 months had passed. By contrast, in the KEYNOTE trials that figure was far smaller, only 4% to 6%. On top of that, this cohort included the patients with the highest baseline median and mean tumor burden of anyone in our study, and compared with the single agent pembrolizumab trials, it had a greater share of patients whose histology was squamous. We think the interplay among these elements could have played a role in the unexpectedly high overall response rates observed in this group. In the cohort of patients over 50%, where 15 patients were efficacy evaluable, we are happy to report that 13% achieved a complete response on the doublet regimen. As we stated before, we didn't anticipate any meaningful bump in overall response rates within this group, since pembrolizumab as a single agent already yields a fairly high overall response rate. And with such a limited number of patients—15 in this instance—the overall response rate came in at 40%, which we recognized might make it hard to demonstrate a difference. So the ORR we showed matched our expectations for the trial; even so, we had hoped going into the study that we might observe, even in a small group of patients, a better quality of responses than what single agent pembrolizumab usually produces. Thanks to multiple complete responses, we accomplished that, and those patients with complete responses remain responders and continue receiving treatment for more than 1 year and more than 2 years, respectively. Altogether, throughout the non-small cell lung cancer cohorts, the median depth of response among all responders was 72%, per blinded independent review, and this was likewise something we had wanted to see in the study. Looking at what came out of PROPEL, there are several key things that leave us feeling good. To start with, the response rate overall and how deep those responses went in the group under 1% really stood out. Among patients who responded and had a meaningful depth of response, we saw ORR double. Next, when you look across the cohorts, both how deep and how long the responses lasted were impressive — median depth of response came in at 72% overall, and the median response hadn't been reached yet. In the 50% cohort, the complete response rate was 13%, which mirrors what we've come to see with BEMPEG. In other tumor types — whether it's chemo plus IO or IO alone in lung cancer — complete responses don't happen often. One thing worth pointing out is that a few things made the patients in this study harder to treat overall, and the same was true in the keynote studies—things like a lot of tumor burden and having had chemotherapy before for metastatic disease, particularly in the 1 to 49 groups. In PROPEL, patients are also receiving a larger dose of BEMPEG, 0.01 milligrams per kilogram, together with pembrolizumab. This group is still early and still enrolling, so while we've seen adverse events rise with the higher dose, most patients haven't gotten far enough into their scan cycles for us to assess how well it's working. We're still keeping an eye on this cohort. But since first-line non-small cell lung cancer treatment usually includes chemo as part of the backbone, and given how chemo has worked historically against non-small cell lung cancer, we're going to concentrate our development efforts on the chemotherapy combination arms within PROPEL to inform what we do next in this setting. So given how well BEMPEG is tolerated at 0.006 milligrams per kilogram, and because of the signal we saw in the doublet, we're pairing BEMPEG with pembrolizumab plus chemotherapy at that same 0.006 milligrams per kilogram dose. In that vein, as Howard said earlier, we recently added an arm to PROPEL that combines it with chemotherapy. The rationale behind that choice was to give ourselves a possible route to registration built around the standard of care that's actually appropriate for patients whose PD-L1 falls under 50%. More than 70% of patients have tumors expressing below that 50% threshold. For the majority of those people, treatment involved a chemo-containing regimen. Immuno-oncology monotherapy doesn't get used much in that context. We also recognize that within the greater-than-50% cohort, roughly 50% get pembrolizumab by itself. Around the middle of 2022, we could potentially report preliminary findings from the trial's chemotherapy combination arm. Regarding how we'll design a complete registrational pathway for BEMPEG in non-small cell lung cancer, what we learn from the entirety of PROPEL will serve as our compass. Turning to the fresh Phase II/III registrational trial in head and neck cancer, enrollment has just gotten underway, and we aim to randomize our first patient before this year ends.

Dimitry Nuyten

executive
#6

For this trial, we've got partnerships set up with Merck as well as SFJ Pharmaceuticals, and we're really enthusiastic about the chance to serve a sizable group of patients in the frontline setting. This study, which involves more than 500 patients, is built to enable possible worldwide registration of BEMPEG combined with pembrolizumab in head and neck cancer; it features an interim look at overall response rate once 200 patients have been enrolled. Should that overall response rate clear a futility boundary set in advance, the trial will move forward, and the other 300 patients are going to be enrolled into the Phase III part of the study. In that Phase III portion, a total of 500 patients are going to be assessed for the primary endpoint of overall response rate along with overall survival. Because the competitive landscape looks favorable, we view this as a one-of-a-kind chance for us to make BEMPEG the first IL-2-based mechanism approved to treat head and neck cancer; so I'll now hand the call over to JZ, who is going to walk through the NKTR-255 program as well as our NKTR-358 program. JZ?

Jonathan Zalevsky

executive
#7

I appreciate that, Dimitry. I'll begin by discussing NKTR-255, which is an agent designed to interact with the entire IL-15 pathway, delivering functional activation along with homeostatic regulation of IL-15 responses in immune cells—specifically natural killer cells, CD8 T cells, and immune memory subsets. Because it acts as an agonist across the whole IL-15 pathway, NKTR-255 is able to pair with a variety of mechanisms, from targeted agents to cellular therapies and even immunological checkpoints, with the goal of potentially boosting their effectiveness. As Howard noted, our early approach centers on pairing it with antibodies that work via an ADCC mechanism of action. We also have a strong clinical program underway covering both liquid and solid tumors. Our newly announced clinical partnership with Merck KGaA and Pfizer represents another step forward in that approach. Avelumab stands alone as the immunotherapy that has shown a survival benefit among patients with locally advanced or metastatic urothelial carcinoma whose disease has not progressed following first-line platinum-containing chemotherapy; as a result, it has quickly secured the leading market position in this indication. We're thrilled to pair NKTR-255 with that market leader, and we look forward to drawing on the combined expertise of Merck and Pfizer to expand our NKTR-255 development program. The JAVELIN Bladder Medley study is a worldwide, multicenter Phase II umbrella trial designed to assess avelumab as a single agent against the combination of avelumab plus NKTR-255 in this maintenance setting. The NKTR-255 combination group in the trial is set to enroll 72 patients, and it will be measured against the 36-patient avelumab group. Results from this study will help establish whether a registrational path exists for NKTR-255 in this setting, where avelumab already holds approval. The avelumab alliance of Merck and Pfizer is funding the trial, with Merck serving as the lead. Merck remains on schedule to launch the study during the first quarter of 2022. Our 2 active NKTR-255 studies—one in liquid tumors and one in solid tumors—are moving forward, and we anticipate sharing data from them in the weeks ahead. At SITC next week, we'll present the first patient data from the initial dose escalation cohorts of our trial, which assesses NKTR-255 combined with cetuximab across 2 separate groups of heavily refractory late-line patients: one group with metastatic colorectal cancer and the other with head and neck cancer. As Howard said earlier, dose escalation in this trial is still underway. We'll hold an analyst event on Friday, November 12, during the SITC Congress. The event will include a guest key opinion leader, Dr. Alan Tan from Rush Medical Center, who will join us. In our Phase I/II trial of NKTR-255 for patients with relapsed refractory hematologic malignancies, the agent has been very well tolerated as a monotherapy, and we continued dosing as dose escalation proceeded. Consequently, dose escalation remains ongoing, and we now anticipate finishing the dose escalation portion of the trial in the first part of 2022. We're also really happy that the dose escalation data got accepted for a presentation at ASH this year, taking place in Atlanta in December. Those findings expand upon what we shared at SITC 2020 regarding NKTR-255 in hematological malignancies, and they pave the way for pairing NKTR-255 with the ADCC agents rituximab and daratumumab in non-Hodgkin's lymphoma and multiple myeloma patients, respectively; and once dose escalation is done, we'll move into further arms. In the first arm of this study, NKTR-255 will be assessed either alone or alongside rituximab in third line or later follicular lymphoma or low-grade non-Hodgkin's lymphoma. Arm two will look at NKTR-255 both as a monotherapy and combined with DARZALEX FASPRO in third line or greater multiple myeloma. Then lastly, arm three will test NKTR-255 as a monotherapy for non-Hodgkin's lymphoma patients whose disease has progressed after prior approved CD19 CAR T cell therapy. Additionally at ASH, investigators from the Fred Hutchinson Cancer Research Center are going to share initial results from a safety and pharmacodynamic analysis of CAR T cell persistence following NKTR-255 treatment. While these findings are preliminary, they show encouraging safety and tolerability, plus signs of CAR T cell rescue after NKTR-255 treatment, demonstrating how NKTR-255 might boost CD8 T cell proliferation and thereby extend how long CAR T cell therapy persists. Now let's shift to our immunology program, NKTR-358. Like Howard mentioned before, we're quite happy with the wide-ranging development and general progress of the NKTR-358 program that our partner Eli Lilly is carrying out. Numerous autoimmune and inflammatory conditions, such as systemic lupus and ulcerative colitis, come with lowered Treg counts, diminished Treg function, and/or less IL-2 production; and through NKTR-358, we aim to tackle these Treg issues and create an IL-2-like molecule capable of selectively stimulating Tregs more effectively than low dose IL-2. Lilly has 2 Phase II trials underway, one for lupus and one for ulcerative colitis. Lilly is also pushing forward 2 distinct Phase Ib studies in psoriasis and atopic dermatitis. The Phase II lupus study is moving along quite well. To recap, 280 patients are being randomized across 1 of 3 NKTR-358 doses or a placebo, given every 2 weeks over a 24-week treatment period. The primary endpoint is the proportion of patients who achieve a reduction of at least 4 points on the SLE disease activity index, or SLEDAI scale. Standard clinical composite endpoints typically used in lupus trials, such as BICLA, are part of the secondary endpoints too; we anticipate finishing this study in the coming 12 to 18 months. Earlier in the year, Lilly started enrolling patients in a Phase II randomized placebo-controlled trial for those with ulcerative colitis. Using an adaptive design, the study will assess several dose levels during the initial induction phase. The plan is to enroll 200 patients in total. The trial's endpoint is the proportion of patients achieving clinical remission following induction therapy at 12 weeks. Beyond that, Lilly intends to keep expanding the NKTR-358 development program. Two more Phase II studies are planned, set to begin in new indications soon. Lastly, we anticipate a possible presentation stemming from the ongoing Phase Ib work in psoriasis and atopic dermatitis, with results from at least 1 of those studies slated for a medical meeting within the coming year. Lilly's dedication to NKTR-358 pleases us, as does their swift progress of the clinical development program and their wish to develop this agent quite broadly across inflammatory and autoimmune diseases. With that, I'll hand the call to Gil.

Gil Labrucherie

executive
#8

Thank you, JZ, and good afternoon to all of you. During this call, I will go over the financial guidance we have for 2021, and that covers a decrease in our projected full year GAAP R&D expense along with a matching rise in our cash position at year-end; we closed out the third quarter sitting in an unusually robust financial spot, holding $955 million in cash and investments, with no debt whatsoever on the balance sheet. Our expectation now is to finish the year holding more than $800 million in cash and investments, which is $50 million higher than the $750 million we had guided previously. For the full year, our GAAP revenue guidance stays the same at roughly $100 million, and that figure contains $15 million to $20 million from product sales plus $80 million to $85 million in noncash royalties. When it comes to full year GAAP R&D expense, we now anticipate a range of $425 million to $430 million. Enrollment for the first-line metastatic melanoma, RCC and bladder studies has been fully completed, so our registrational trials for BEMPEG remain on track. We are quite happy with how quickly the adjuvant study is enrolling, and enrollment has now begun in the head and neck study. Within our R&D expense guidance sits roughly $85 million of noncash expenses, which come from stock compensation, depreciation and the expense tied to the head and neck cancer study that SFJ is funding. Our G&A expense guidance remains projected at between $120 million and $125 million, and it includes $35 million of noncash depreciation and stock compensation expense. We expect noncash interest expense to land between $50 million and $60 million, which stems from the royalty stream monetization we completed earlier. On top of that, our nonoperating expense contains about $15 million tied to accounting for the contingent success based payments to SFJ as a derivative liability. With all of that said, we will now open the call for questions. Operator?

Chris Zopf

analyst
#9

CJ Zopf here, filling in for Chris this evening. We appreciate the news about the PROPEL results. I want to make sure I understand: from what you're saying, the pembro doublet won't move forward as a chemotherapy-sparing approach given how the data look. Also, any sense of when an initial glimpse might come from those chemo cohorts that are set to begin shortly?

Jennifer Ruddock

executive
#10

Jennifer Ruddock here — hi, CJ. Those 2 questions are ones I'll hand over to Dimitry. Was there anything else you wanted to add? My apologies for cutting you off.

Chris Zopf

analyst
#11

No, that was it.

Jennifer Ruddock

executive
#12

Okay, great. Dimitry?

Dimitry Nuyten

executive
#13

Thanks for asking. Over the past seven days, we received the last set of results from the independent analysis of PROPEL, and as a result, we require additional time to review those results more thoroughly. In addition, there will be ongoing monitoring of 15 patients who are still receiving treatment within the trial, along with, shall we say, the production of findings for BEMPEG combined with pembrolizumab and chemotherapy. Therefore, considering all of this information together, we will be, let's say, reaching a completely informed conclusion about the lung cancer approach. PROPEL gave us several quite noteworthy insights — above all the metrics, since supporting data for those is hard to come by in non-small cell lung cancer, along with the response depth we observed. Our goal is to ensure that BEMPEG's edge gets fully utilized within our development plan. At this point, our efforts center largely on chemotherapy combination approaches for low expressors, given that a chemo backbone represents the suitable regulatory route for such patients, as it aligns with standard of care. As everyone is aware, multiple Phase III setbacks have shown up in this area lately — some within just the past 30 days, and a number of others prior to that. Not long ago, there was a treatment approach aimed at reducing chemo use, coming out of ESA's Phase III program — specifically the LEAP 7 trial, which looked at pembrolizumab alongside afatinib in patients whose expression exceeded 1%. That study got halted ahead of schedule during a DMC review, which you could describe as an interim analysis conducted by the DMC. We're aware that findings are going to be shared at ESMO I-O, so examining those data closely is definitely something we want to do. In addition, they have a chemotherapy combo study underway called the LEAP 6 trial, with results anticipated sometime next year. Second, Novartis recently shared results from CANOPY-1. That study looked at pembro alongside the IL-1beta inhibitor canakinumab and chemo, compared against pembro plus chemo. Novartis said the trial missed its primary endpoints for OS and PFS, in both squamous and non-squamous groups. Still, Novartis pointed out that several subsets showed clinically meaningful improvements. So that's certainly something worth examining. But to pull my answer together and get back to what you were really asking, our biggest interest lies in the chemo combination approach for low expressors as the way forward.

Jay Olson

analyst
#14

I appreciate the update regarding PROPEL. Might you tell us about any possible read across that could come from what you've initially learned once you've reviewed those data — anything that might carry over to additional trials involving BEMPEG?

Jennifer Ruddock

executive
#15

Thank you, Jay. Dimitry, would you be willing to take that one?

Dimitry Nuyten

executive
#16

Okay. At this point, I'd say the ability to draw conclusions for other tumor types would be fairly limited. What we can potentially extrapolate comes from certain favorable signals we've observed, what we understand BEMPEG is capable of—making responses deeper and producing CRs—but translating findings between one tumor type and another requires caution, in my view. Take non-small cell lung cancer versus melanoma: these are quite distinct. As I mentioned during the call, melanoma responds strongly to immune-based approaches, whereas non-small cell lung cancer, we know, is less immune-sensitive and has historically always been managed with chemotherapy. Even today, chemo remains the backbone of therapy for most patients; conversely, with melanoma, there's a substantial and highly predictable track record of IL agents doing extremely well. IL-2 itself received approval in melanoma. And before IL agents came along—most notably the checkpoint inhibitors in recent years—chemotherapy for melanoma specifically was truly an inferior option. Meanwhile, for non-small cell lung cancer, chemo has represented a workable standard-of-care choice. So we genuinely view these as 2 separate tumor types in 2 separate contexts. And, say, with the PROPEL data, naturally, we're examining how well BEMPEG can generate deep and lasting responses. That may be something that carries over as a general mechanism, yet overall immune sensitivity differs greatly. And just to remind everyone, for instance, what we've already published for our melanoma cohort at a 29-month follow-up showed an overall response rate of 53% and a complete response rate of 34%; plus, say, the median shift in target lesion size came to nearly 80%—so I'd call that a very, very distinct data set.

Daniel Wolle

analyst
#17

I'm calling in for Jessica. From what was said in the prepared remarks, did I understand correctly that the final chemo data is expected around the middle of 2022? And if that's right, would you have to — would a decision about the path forward need to wait until then? .

Jennifer Ruddock

executive
#18

Thank you, Daniel. I'll turn it over to Dimitry for his perspective on that. Dimitry?

Dimitry Nuyten

executive
#19

Right, that's accurate. What we're looking for, I'd say, is the initial complete safety data package along with the first efficacy results around the midpoint of 2022. Naturally, examining those results will be essential to shape how we approach Phase III. Yet, as I mentioned earlier, we already possess substantial information from PROPEL, and we intend to dig deeper into that; so meanwhile, we'll be developing various plans for what comes next, and once the definitive findings on the chemotherapy combination arrive, we'll use them to complete our strategy.

Greg Harrison

analyst
#20

So what are you doing right now to get ready for a BEMPEG launch, considering that in the best case it might reach the market in roughly 12 months?

Jennifer Ruddock

executive
#21

I'll turn that one over to Gil.

Gil Labrucherie

executive
#22

Appreciate that question, Greg. Yes, quite a few actions are underway on our side. Howard mentioned during his opening comments that if the data arrives in the early portion of '22, a commercial launch could potentially happen by the close of 2022. So alongside our team and BMS, we've been figuring out a sensible sequence for building out everything needed—distribution capabilities, support programs for patients, and every other element required to make the drug accessible, across both the U.S. and Europe. That leaves us feeling very well positioned. Our investments have been the correct ones, appropriate for each stage, and we've collaborated with Bristol on getting ready for launch. So our confidence is high regarding where we stand heading into next year's data readout.

Andy Shay

analyst
#23

So Dimitry, I got curious — earlier you brought up a company, and the FDA did an analysis essentially examining how response depth lines up with how long a response lasts, especially when it comes to checkpoint IO agents. I'm just wondering whether that's sort of a pattern you also observed with PROPEL. And if it's okay, I've got a question for JZ too, specifically about the ASH abstract on 255. You talked about combining with CAR T and sort of reactivating those CAR T cells. I'm just wondering if you have any hypothesis regarding the best timing for giving 255 to really get the most out of this response.

Jennifer Ruddock

executive
#24

Great. Thanks, Andy. JZ, I'll have you answer the 255 question first, and then Dimitry, could you take Andy's question regarding depth of response correlating with other metrics. Go ahead, JZ.

Jonathan Zalevsky

executive
#25

Andy, I appreciate you asking that. So, one thing we've noticed — and this goes back, as you might remember, to the preclinical work — is that when animals received the identical CD19 CAR that's on the market as an approved product, giving them NKTR-255 led to those cells sticking around longer. The overall result wasn't merely more cells over time; it also meant better effectiveness when it came to those cells' capacity to destroy tumors. That was the preclinical side. In this ongoing heme trial, what we chose to do was permit patients whose response to CAR T had been suboptimal — basically a CAR-T failure, those who hadn't achieved durable CRs — to be included in that trial as well, and they then received NKTR-255 as one of the groups in that study; consequently, quite a few participants in the trial are post CAR-T. Since last year, at 2020, as you'll recall, we presented a single case study in which a patient had received a CAR T therapy 4 months earlier, before starting NKTR-255 treatment. Following administration of NKTR-255, that individual showed a rise in CAR T cell numbers; so we're eager to build on those findings at ASH this year. We now have a greater number of patients, more individuals enrolled and treated with 255. That means we can add far more patients to that analysis within the post CAR-T context. So this has been quite an exciting area and, as you're aware, a distinctive niche within the treatment options available to these patients. Now, regarding the other part of what you asked — the timing element — that's something we're considering extremely carefully. Clearly, in this first-in-human trial, the patients we treat are CAR-T failures. They therefore arrive long after their CAR-T experience. Yet as we move NKTR-255 forward in a CAR-T combination or even with other cell therapies, we're in fact quite actively investigating how the dosing of the 2 agents should be timed relative to one another. We possess substantial preclinical data helping us grasp this, covering both the order of administration and the gaps in time separating doses. That's the sort of reasoning we'll incorporate into the study once we conduct it.

Jennifer Ruddock

executive
#26

Appreciate that, JZ. Dimitry, would you mind fielding Andy's question regarding how depth of response correlates with other clinical benefit in lung cancer?

Dimitry Nuyten

executive
#27

Of course. Yes, I appreciate that question. As you mentioned, the FDA has carried out thorough work to link, shall we say, those endpoints and to establish that, shall we say, how good a response is matters a great deal; that is among the reasons it is something we closely examine in our data, along with the count of statements I provided regarding it, the depth of responses we have observed, the count of CRs, and then the count of patients whose target lesions show 100% tumor volume reduction; so those individuals are partial responders if a target lesion remains that has not fully vanished; yet clearly, that also represents a far deeper response than what someone with less volume reduction has; so those are the facts we possess. That is why we feel enthusiastic about several findings from the trial. I can give you a direct answer to your question, noting that obviously, our study would not be mature for overall survival, considering how much follow-up there is and the fact that the median has not been reached; however, in a highly exploratory analysis, given where we stand in the trial at this time with fairly short follow-up for survival, we do observe, shall we say, a trend pointing the right way, with a correlation between depth of response and both PFS and OS. And once more, I want to stress that within a small trial and with limited follow-up, clearly, this is purely an exploratory analysis, yet we can see that correlation.

Howard Robin

executive
#28

Well, thanks to each of you for being with us today. Nektar is definitely entering a stretch that's both very active and thrilling. We're hoping you'll be on our calls regarding the data presentations at SITC and ESMO I-O. Also, we have our eyes on the registrational readouts for BEMPEG, starting with the melanoma results everyone's eagerly waiting for in the early portion of next year. I want to express gratitude to every one of our staff members for what they've done to help us hit these milestones throughout this extremely, extremely tough time. And my thanks go out to our shareholders for sticking with us. We're eager to bring you news about how we're advancing. So keep watching. Thank you so much.

Operator

operator
#29

That brings us to the end of this conference call. We appreciate everyone taking part, and at this point you're free to disconnect. Have a great day, everybody.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.